Skip to main content

Table 6 Base-case cost and effectiveness results of treatment strategies (per patient)

From: Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

Discounted (3% annual discount rate)

Second-line agent add-on to Metformin

Total

Incremental

Costs

LYs gained

Costs

LYs gained

ICER

Sulfonylurea

$7004

11.81

   

Dipeptidyl peptidase-4 inhibitor

$18853

12.42

$11849

0.61

$19420

Undiscounted

Sulfonylurea

$10501

15.68

   

Dipeptidyl peptidase-4 inhibitor

$28013

16.70

$17512

1.02

$17170

  1. All costs were expressed in 2015 US dollars ($)
  2. Acronyms: LY-Life-year, CER-cost-effectiveness ratio (equal to cost/LY), ICER- incremental cost-effectiveness ratio (equal to incremental cost/incremental LYs)